Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Rhea-AI Summary

Aptorum Group (NASDAQ: APM) announced receipt of a Nasdaq notification dated March 5, 2026, for non-compliance with the $1 minimum bid price under Nasdaq Listing Rule 5550(a)(2).

The notification does not affect current trading. Aptorum has a 180-calendar-day cure period until September 1, 2026, to regain compliance and is evaluating options, including a possible reverse stock split, to restore compliance.

Positive

• Nasdaq granted a 180-calendar-day cure period through September 1, 2026
• Notification does not immediately affect listing or trading of APM shares

Negative

• Non-compliance with Nasdaq minimum bid price requirement under Rule 5550(a)(2)
• Company is considering a reverse stock split as a potential remedy

Market Context

This announcement highlights APM’s receipt of a Nasdaq notice for falling below the $1 minimum bid p...

Analysis

This announcement highlights APM’s receipt of a Nasdaq notice for falling below the $1 minimum bid price, triggering a 180-day window to regain compliance that may include a reverse stock split. In context, the company already has a $75,000,000 mixed shelf and a pending merger with DiamiR that would reshape ownership to about 70%/30%. Investors may monitor progress on merger approvals, capital-raising activity under the shelf, and any corporate actions aimed at restoring the bid price above $1.

Key Figures

Nasdaq bid requirement: $1 per share Grace period: 180 calendar days Shelf size: $75,000,000 +5 more

8 metrics

Nasdaq bid requirement $1 per share Minimum bid price per Nasdaq Listing Rule 5550(a)(2)

Grace period 180 calendar days Period to regain Nasdaq minimum bid compliance to Sept 1, 2026

Shelf size $75,000,000 Mixed shelf registration on Form F-3 filed Jan 16, 2026

Shares outstanding 6,346,823 shares Class A Ordinary Shares as of Jan 14, 2026 (F-3 summary)

Public float $7.55 million Public float limiting primary F-3 sales under Instruction I.B.5

Resale shares 54,054 shares Class A Ordinary Shares registered for resale via outstanding warrants

Warrant exercise price $0.00 Exercise price of selling shareholder warrants in F-3 summary

Post-merger ownership 70% / 30% Expected split DiamiR holders vs current Aptorum shareholders after merger

Historical Context

4 past events · Latest: Feb 02 (Positive)

Pattern 4 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 02	Collaboration update	Positive	-10.2%	Collaboration to validate INB’s APOE testing platform in DiamiR’s lab.
Nov 19	Conference abstracts	Positive	+3.9%	Two CTAD 2025 Alzheimer’s biomarker abstracts accepted for presentation.
Oct 10	Registered offering	Negative	-30.0%	Up to $6M registered direct equity financing plus warrants for merger funding.
Oct 09	Merger governance	Positive	-1.7%	Board and management changes tied to planned DiamiR stock-for-stock merger.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

News reactions are mixed: positive collaboration and conference updates produced both gains and losses, while the October 2025 financing aligned with a sharp selloff. Corporate/merger governance news also saw a modest negative reaction.

Recent Company History

Over the past several months, APM has issued collaboration, conference, merger, and financing updates. A February 2026 collaboration announcement with DiamiR/INB was followed by a -10.22% move, while November 2025 CTAD conference abstracts saw a 3.85% gain. An October 2025 registered direct offering linked to merger funding coincided with a -29.96% drop. The prior day’s merger-related board expansion news led to a milder -1.66% reaction. Against this backdrop, the Nasdaq minimum bid-price deficiency highlights ongoing listing risk after prior capital-raising and merger steps.

Key Terms

minimum bid price requirement, reverse stock split

2 terms

minimum bid price requirement regulatory

"regarding non-compliance with the minimum bid price requirement of $1 per share"

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

reverse stock split financial

"options to restore compliance, including, if necessary, a reverse stock split"

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Hong Kong, March 06, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM), a leading Biotechnology company, today announced that it has received a notification from the Nasdaq Stock Market LLC dated March 5, 2026 regarding non-compliance with the minimum bid price requirement of $1 per share, as per Nasdaq Listing Rule 5550(a)(2).

The notification does not immediately affect the listing or trading of the company’s shares on Nasdaq. Aptorum Group Limited has been granted a 180-calendar-day grace period, until September 1, 2026, to regain compliance with the noted listing requirement.

During this period, Aptorum Group Limited intends to evaluate all available options to restore compliance, including, if necessary, a reverse stock split. The company is committed to maintaining its Nasdaq listing and will take all reasonable measures to achieve compliance within the stipulated time frame.

About Aptorum Group Limited

Aptorum Group Limited is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. These statements reflect the company’s current expectations and projections about future events and are based on assumptions. Actual results may differ materially from those projected.

For further information, please contact: investor.relations@aptorumgroup.com

FAQ

What does the Nasdaq notification mean for Aptorum Group (APM)?

It means APM is below Nasdaq's $1 minimum bid price requirement and is formally non-compliant. According to Aptorum Group, the notice starts a compliance period and does not immediately affect listing or trading while the company works to regain compliance.

How long does Aptorum Group (APM) have to regain compliance with Nasdaq?

Aptorum Group has a 180-calendar-day cure period ending September 1, 2026 to regain compliance. According to Aptorum Group, the period runs from the March 5, 2026 notice date and gives the company time to evaluate remedial options.

Will Aptorum Group (APM) be delisted from Nasdaq after the notice?

The notice does not immediately trigger delisting; trading continues while the cure period is active. According to Aptorum Group, the company will use the 180-day period to pursue compliance before any further listing actions would be considered.

What actions is Aptorum Group (APM) considering to regain Nasdaq compliance?

The company intends to evaluate all available options, which may include a reverse stock split to increase the per-share price. According to Aptorum Group, management will assess remedies during the cure period to restore compliance by September 1, 2026.

How does the Nasdaq notice affect APM shareholders in the short term?

Short-term trading and listing are not directly affected by the notice while the cure period is active. According to Aptorum Group, shareholders should expect the company to explore options to regain compliance, which may influence future share structure or liquidity.